Literature DB >> 24657626

Towards a sustainable system of drug development.

Ellen H M Moors1, Adam F Cohen2, Huub Schellekens3.   

Abstract

Drug development has become the exclusive activity of large pharmaceutical companies. However, the output of new drugs has been decreasing for the past decade and the prices of new drugs have risen steadily, leading to access problems for many patients. By analyzing the history of drug development and the pharmaceutical industry, we identified the main factors causing this system failure. Although many solutions have been suggested to fix the drug development system, we believe that a combination of reforms of the regulatory and patent systems is necessary to make drug development sustainable. These reforms must be combined with a larger, open-access role for public research institutes in the discovery, clinical evaluation and safety evaluation of new drugs.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24657626     DOI: 10.1016/j.drudis.2014.03.004

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  12 in total

1.  Making individualized drugs a reality.

Authors:  Huub Schellekens; Mohammed Aldosari; Herre Talsma; Enrico Mastrobattista
Journal:  Nat Biotechnol       Date:  2017-06-05       Impact factor: 54.908

2.  Pharmaceutical pricing conundrum: time to get rid of it?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2018-11

Review 3.  Multistep enzyme cascades as a route towards green and sustainable pharmaceutical syntheses.

Authors:  Ana I Benítez-Mateos; David Roura Padrosa; Francesca Paradisi
Journal:  Nat Chem       Date:  2022-05-05       Impact factor: 24.274

Review 4.  Engineering complexity in human tissue models of cancer.

Authors:  Kacey Ronaldson-Bouchard; Ilaria Baldassarri; Daniel Naveed Tavakol; Pamela L Graney; Maria Samaritano; Elisa Cimetta; Gordana Vunjak-Novakovic
Journal:  Adv Drug Deliv Rev       Date:  2022-03-09       Impact factor: 17.873

5.  What the public knows and wants to know about medicines research and development: a survey of the general public in six European countries.

Authors:  Suzanne Parsons; Bella Starling; Christine Mullan-Jensen; Su-Gwan Tham; Kay Warner; Kim Wever
Journal:  BMJ Open       Date:  2015-04-08       Impact factor: 2.692

Review 6.  Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact.

Authors:  Remco L A de Vrueh; Daan J A Crommelin
Journal:  Pharm Res       Date:  2017-06-06       Impact factor: 4.200

Review 7.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

8.  What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview study.

Authors:  Suzanne Parsons; Bella Starling; Christine Mullan-Jensen; Su-Gwan Tham; Kay Warner; Kim Wever
Journal:  BMJ Open       Date:  2016-01-07       Impact factor: 2.692

9.  Views of European Drug Development Stakeholders on Treatment Optimization and Its Potential for Use in Decision-Making.

Authors:  Robbe Saesen; Stéphane Lejeune; Gianluca Quaglio; Denis Lacombe; Isabelle Huys
Journal:  Front Pharmacol       Date:  2020-02-05       Impact factor: 5.810

10.  Improving the odds of drug development success through human genomics: modelling study.

Authors:  Aroon D Hingorani; Valerie Kuan; Chris Finan; Felix A Kruger; Anna Gaulton; Sandesh Chopade; Reecha Sofat; Raymond J MacAllister; John P Overington; Harry Hemingway; Spiros Denaxas; David Prieto; Juan Pablo Casas
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.